title: [High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study].
authors.affiliation: I. Univers.-Frauenklinik Wien.
authors.forename: E
authors.initials: E
authors.lastname: Küffer
authors.forename: B
authors.initials: B
authors.lastname: Fazeny
authors.forename: P
authors.initials: P
authors.lastname: Speiser
authors.forename: C
authors.initials: C
authors.lastname: Kurz
authors.forename: N
authors.initials: N
authors.lastname: Vavra
authors.forename: P
authors.initials: P
authors.lastname: Sevelda
authors.forename: C
authors.initials: C
authors.lastname: Dittrich
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D009944:Organoplatinum Compounds; D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D007069:Ifosfamide